PD-L1 Antibody

49251-100ul SAB 100ul 399.6 EUR

PD-L1 Antibody

49251-50ul SAB 50ul 286.8 EUR

PD-L1 Antibody

P1013-01m SAB 0.1m 224.4 EUR

PD-L1 Antibody

P1013-1ml SAB 1ml 807.6 EUR

PD-L1 Antibody

R31573 NSJ Bioreagents 100 ug 356.15 EUR
Description: Programmed death-ligand 1, also known as CD274 or B7-H1 is a protein that in humans is encoded by the CD274 gene. It is a 33-70kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Upregulation on tumor MDCs downregulates T-cell immunity and PD-L1 blockade may represent an approach for cancer immunotherapy. It can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. It has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer.

PD-L1 Antibody

R33263-100UG NSJ Bioreagents 100 ug 339.15 EUR
Description: Additional name(s) for this target protein: Programmed cell death 1 ligand 1; CD274

PD-L1 Antibody

DF6526 Affinity Biosciences 100ul 280 EUR
Description: Human,Mouse,Rat

PD-L1 Antibody

DF6526-100ul Affinity Biosciences 100ul 280 EUR

PD-L1 Antibody

DF6526-200ul Affinity Biosciences 200ul 350 EUR

Anti-PD-L1 Antibody

A1454-100 Biovision each 405.6 EUR

Anti-PD-L1 Antibody

A1454-30T Biovision each 175.2 EUR

Anti-PD-L1 antibody

STJ180217 St John's Laboratory 0.1 ml 336 EUR

Anti-PD-L1 antibody

STJ180383 St John's Laboratory 0.1 ml 295.2 EUR

Anti-PD-L1 antibody

STJ190082 St John's Laboratory 200 µl 236.4 EUR
Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7)

Anti-PD-L1 antibody

STJ130022 St John's Laboratory 50 µl 385.2 EUR
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody

STJ130023 St John's Laboratory 50 µl 385.2 EUR
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody

STJ130024 St John's Laboratory 50 µl 385.2 EUR
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

PD-L1 Antibody [F6A9]

SD8639-002mg ProSci 0.02 mg 253.22 EUR
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F6A9]

SD8639-01mg ProSci 0.1 mg 723.62 EUR
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F2G2]

SD8641-002mg ProSci 0.02 mg 253.22 EUR
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F2G2]

SD8641-01mg ProSci 0.1 mg 723.62 EUR
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

Mouse PD-L1 Antibody

32903-05111 AssayPro 150 ug 313.2 EUR

PD-L1/CD274 antibody

CAF50592-100ug Biomatik Corporation 100ug 312 EUR

PD-L1 Conjugated Antibody

C49251 SAB 100ul 476.4 EUR

PD-L1 Monoclonal Antibody

CAC10271-100ul Biomatik Corporation 100ul 367.5 EUR

PD-L1 Monoclonal Antibody

CAC10271-50ul Biomatik Corporation 50ul 252 EUR

PD-L1 Polyclonal Antibody

E911273a EnoGene 100ul 225 EUR
Description: Available in various conjugation types.

anti- PD-L1/CD274 antibody

FNab06280 FN Test 100µg 606.3 EUR
Description: Antibody raised against PD-L1/CD274

anti- PD-L1/CD274 antibody

FNab06281 FN Test 100µg 658.5 EUR
Description: Antibody raised against PD-L1/CD274

anti-PD-L1 VHH antibody

JOT0002-5 Jotbody each Ask for price

anti-PD-L1 VHH antibody

JOT0002-5-1-100 Jotbody 100 148.12 EUR
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody

JOT0002-5-1-1000 Jotbody 1000 880.6 EUR
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody

JOT0002-5-1-2000 Jotbody 2000 1565.2 EUR
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody

JOT0002-5-1-250 Jotbody 250 246.17 EUR
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody

JOT0002-5-1-50 Jotbody 50 89.54 EUR
Description: Primary VHH single domain antibody

PD-L1 Antibody (IHC Gold)

E36PA411 EnoGene 100ul 225 EUR
Description: Available in various conjugation types.

Anti-PD-L1/CD274 Antibody

PB9994 BosterBio 100ug/vial 352.8 EUR

Anti-PD-L1/CD274 Antibody

PB9154 BosterBio 100ug/vial 352.8 EUR

Anti-PD-L1/CD274 Antibody

PA1851 BosterBio 100ug/vial 352.8 EUR

Anti-PD-L1/CD274 antibody

PAab06280 Lifescience Market 100 ug 426 EUR

Anti-CD274 / PD-L1 antibody

STJ70646 St John's Laboratory 100 µg 430.8 EUR

Anti-PD-L1 Antibody (IHC411)

A1549-50 Biovision each 222 EUR

OASL01224-50UL - PD-L1 Antibody

OASL01224-50UL Aviva Systems Biology 50ul 269 EUR

Rabbit Polyclonal PD-L1 Antibody

TA306401 Origene Technologies GmbH 100 µg Ask for price

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody

20-abx319445 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ribosome-inactivating protein PD-L1/PD-L2 Antibody

1-CSB-PA306294LA01PJJ Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA

Anti-PD-L1 Antibody [PD01-02]

HA721176 HUABIO 100ul 231 EUR
Description: PD-L1 (programmed-death ligand 1; CD274), is a transmembrane protein constitutionally expressed on a variety of cell types, including antigen presenting cells (dendritic cells and histiocytes) and some non-lymphoid tissues (heart and lung). Binding of PD-L1 to PD-1 (programmed-death 1; CD279) expressed by activated T-cells, inhibits their function, causing negative feedback control of immunological reactions, thus impeding inflammation and autoimmunity. Tumour cells may express PD-L1, which binds to PD-1 allowing cancer cells to evade the attack of T-cells. Blockade of the PD-1/PD-L1 pathway has now shown useful in therapy of multiple cancer types, causing durable tumour regressions in a substantial proportion of otherwise treatment refractory cases of melanoma, and carcinomas of e.g., lung, kidney, and urinary tract. Patients without tumour PD-L1 expression can also derive benefit from blocking agents (studies across multiple cancer types demonstrate a pooled response rate of 48% in patients with PD-L1-positive tumours compared to 15% in PD-L1-negative tumours). Tonsil and placenta can be used as positive and negative tissue controls. However, tonsil is found to be superior to placenta, as tonsil displayes a range of PD-L1 expression levels. Tonsil displayes the following reaction pattern: No staining reaction in the vast majority of lymphocytes including mantle zone and germinal centre B-cells, no staining reaction in superficial epithelial cells, a weak to moderate, typically punctuated membranous staining reaction of the majority of germinal centre macrophages and finally a moderate to strong staining reaction of the majority of epithelial crypt cells.

Anti-PD-L1 Antibody [JJ08-95]

ET1701-41 HUABIO 100ul 231 EUR
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T cell proliferation, cytokine production, differentiation of effector T cells, and the induction of Bcl-x, a promoter of T cell survival. Conversely, engagement of CTLA4 by B7-1 or B7-2 may inhibit proliferation and IL-2 production. Pdcd-1L1 (programmed cell death ligand-1), also known as B7-H1 or PD-L1, is 290 amino acid type I transmembrane protein which is 20% and 15% identical to B7-1 and B7-2, respectively. Pdcd-1L2 has immunoglobulin V-like and C-like domains and a 30 amino acid cytoplasmic tail. It does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of Pdcd-1L1 co-stimulation. The gene which encodes Pdcd-1L1 maps to human chromosome 9p24. Pdcd-1L2 (programmed cell death ligand-2) is a 73 amino acid protein which contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The gene which encodes Pdcd-1L2 maps to human chromosome 9p24.2. The constitutive expression of Pdcd-1L1 and Pdcd-1L2 on paren-chymal cells of heart, lung and kidney suggests that the Pdcd-1-Pdcd-L system could provide unique negative signaling to help prevent autoimmune disease.

Anti-PD-L1 Antibody [JJ08-95]

ET1701-41TR HUABIO 20ul 64.35 EUR
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T cell proliferation, cytokine production, differentiation of effector T cells, and the induction of Bcl-x, a promoter of T cell survival. Conversely, engagement of CTLA4 by B7-1 or B7-2 may inhibit proliferation and IL-2 production. Pdcd-1L1 (programmed cell death ligand-1), also known as B7-H1 or PD-L1, is 290 amino acid type I transmembrane protein which is 20% and 15% identical to B7-1 and B7-2, respectively. Pdcd-1L2 has immunoglobulin V-like and C-like domains and a 30 amino acid cytoplasmic tail. It does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of Pdcd-1L1 co-stimulation. The gene which encodes Pdcd-1L1 maps to human chromosome 9p24. Pdcd-1L2 (programmed cell death ligand-2) is a 73 amino acid protein which contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The gene which encodes Pdcd-1L2 maps to human chromosome 9p24.2. The constitutive expression of Pdcd-1L1 and Pdcd-1L2 on paren-chymal cells of heart, lung and kidney suggests that the Pdcd-1-Pdcd-L system could provide unique negative signaling to help prevent autoimmune disease.

PD-L1 Antibody / B7-H1 / CD274

F55054-0.1ML NSJ Bioreagents 0.1ml 339.15 EUR
Description: As a ligand for the inhibitory receptor PDCD1/PD-1, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response. [UniProt]

PD-L1 Antibody / B7-H1 / CD274

V7822-100UG NSJ Bioreagents 100 ug 349.3 EUR
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274

V7822-20UG NSJ Bioreagents 20 ug 153.3 EUR
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274

V7822SAF-100UG NSJ Bioreagents 100 ug 349.3 EUR
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274

V7823-100UG NSJ Bioreagents 100 ug 349.3 EUR
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274

V7823-20UG NSJ Bioreagents 20 ug 153.3 EUR
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.